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ABSTRACT: Designing biocompatible materials to encapsulate xenogeneic insulin-releasing 
β-cells for transplantation has been considered as a promising alternative to avoid the 
immunosuppression and drawbacks of the treatment of Type 1 diabetes mellitus (T1D) by 
direct islet transplantation. The current work for the first time studied a hybrid alginate@TiO2 
microcapsule as a reservoir for rat insulinoma-derived INS-1E cells, as a β-cell surrogate, 
towards the treatment of T1D. The hybrid microcapsule is composed of an alginate core as a 
biocompatible matrix for cell encapsulation and a crack-free TiO2 shell as a semi-permeable 
membrane to prevent cell leakage, protect encapsulated cells from immune attacks, as well as 
allow the diffusion of nutrients and the secretion of insulin. Compared to most-commonly used 
pure alginate microcapsules, the insulin-secreting INS-1E cells encapsulated in our 
alginate@TiO2 microcapsules revealed higher metabolic activity and maintained the insulin 
secretion over more than 6 weeks. This study highlights that our designed alginate@TiO2 
hybrid microcapsules can serve as an ideal reservoir for cell encapsulation towards the 
treatment of T1D, thus further promoting the development of artificial organs for cell therapy. 
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Type 1 diabetes mellitus (T1D), as a kind of human disorders involving hormone or proteins 
deficiency, has increasingly become a big human health threat nowadays1. It consists in the 
autoimmune destruction of insulin secreting β-cells and hampers thus the glucose homeostasis. 
Currently the most common treatment is the discontinuous insulin injection which remains 
however a major burden in everyday life and cannot eliminate all complications of the disease2. 
Transplantation of islets has evolved into a prospective treatment as it allows the recovery of 
an endogenous insulin secretion and the control of glycaemia in insulin-dependent patients3-4. 
However, this treatment still presents various restrictions such as very limited donor supply, in 
general one donor for 300 patients. Furthermore, a patient requires generally 2-3 donors5. About 
90 % of insulin-dependence recurrence 5-years post-transplantation has been observed6. A 
strong and life-long immunosuppressive medication is also required for patients, which leads 
to various side-effects7-8. 
An alternative to avoid immunosuppression and its drawbacks is to separate the islets (or β-
cells) from the host immune system by introducing a semi-permeable membrane that would 
prevent the entry of immune defenders while allowing the diffusion of essential nutrients, 
oxygen, metabolites and insulin9-13. This kind of cell therapy methodologies has been largely 
used since first introduced by Bisceglie 80 years ago14-17. Alginate-based microcapsules are the 
most-used hydrogels for this medical treatment, because of their high biocompatibility, low 
cytotoxicity, low cost, and mild gelation conditions18-21. For instance, alginate microcapsules 
have been used for the encapsulation of insulin-secreting islet cells in order to restore long-
term euglycemic maintenance without immunosuppression22-23. However, they usually present 
poor mechanical resistance and thus low stability in vitro and in vivo. 
Hybridization of hydrogels with inorganic compounds has been developed as a promising 
method to improve the properties of the hydrogels or equip the hydrogels with new functions 
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to widen their application range or improve their efficiency in applications24-25. For example, the 
incorporation of carbon materials within hydrogels can enhance their electronical 
conductivity26, thus realizing the applications in cell therapy towards cardiac or neural diseases 
or bone injury27-30; hybridizing microcapsules with gold nanoparticles enables to reinforce the 
mechanical strength of hydrogels and facilitate cell adhesion, spreading, and proliferation, 
which makes possible the precise cell differentiation control31; coordinating minerals with 
hydrogels can introduce the hydrogels with controllable stiffness to control the behaviours of 
encapsulated cells precisely32-33. Recently, new structured hybrid microcapsules which are 
composed of inorganic shells and an organic core have been reported and attracted a lot of 
attention34-35. The inorganic shell enhances the stability of the microcapsule and provides 
controlled permeability, while the organic core offers a highly biocompatible environment for 
the encapsulated cells, which makes this structured microcapsule a promising cell reservoir 
with long-term viability and activity for cell therapy36-38. For example, alginate@TiO2 hybrid 
microcapsules have been demonstrated to be a suitable reservoir of HepG2 cells. They showed 
biocompatible and possessed controlled porosity to confirm the long-term cell viability, the 
cell activity, and the release of the cell metabolic39. Importantly, these microcapsules also 
presented high in vivo biocompatibility and in vivo stability when implanted into rats, thus 
contributing to their potential in cell therapy. However, the previous studies were implemented 
based on the model HepG2 cells which do not present any therapeutic use, so that further 
investigation is still highly needed towards practical application of hybrid microcapsules in cell 
therapy.      
Herein, we first time investigate a hybrid alginate@TiO2 microcapsule as a reservoir for 
insulin-secreting β-cells to maintain glucose homeostasis towards the cell therapy of T1D. 
Compared with the most-commonly used pure alginate microcapsules, hybrid alginate@TiO2 
microcapsules present a hard porous inorganic shell which shows enhanced mechanical 
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stability without compromising the nutrient diffusion and insulin secretion, thus preventing the 
leakage of encapsulated cells and providing them with a long-term stable environment for 
growth, proliferation and metabolism. Biocompatible hybrid alginate@TiO2 microcapsules are 
prepared through a facile one-step process under mild conditions. Alginate serves as a matrix 
for cell encapsulation and a template for the formation of TiO2 shells by the hydrolysis and 
condensation of the precursor. Rat insulinoma-derived INS-1E cells, which are able to secrete 
insulin in response to glucose stimulation in the physiological range40-41, are encapsulated in our 
hybrid alginate@TiO2 microcapsules. The morphology and structure of the hybrid 
microcapsules are investigated in detail. The viability of the encapsulated INS-1E cells are 
monitored, as well as their glucose-stimulated insulin secretion, in order to advance the 
development of cell encapsulation techniques for the treatment of T1D.               
 
MATERIALS AND METHOD 
Chemicals. Titanium(IV) bis(ammonium lactato)dihydroxide solution (TiBALDH, 50 wt.% 
in H2O), poly(diallyldimethylammonium) chloride solution (PDDAC, average Mw 100,000-
200,000, 20 wt. % in H2O), alginic acid sodium salt, from brown algae (for immobilization of 
microorganisms), calcium chloride (dihydrate, 99 %), ethylene glycol-bis(β-aminoethyl ether)-
N,N,N’,N’-tetraacetic acid (EGTA, tetrasodium salt, 97 %), hydrochloric acid (Molecular 
Biology Grade, 36.5-38.0 %), sodium hydroxide (reagent grade, 98 %, anhydrous), chloroform 
(anhydrous, 99 %), glutaraldehyde (50 wt. % in H2O), fluorescein diacetate (FDA, used as cell 
viability stain), glucose solution (BioUltra, for molecular biology, ~20 % in H2O), sodium 
chloride (ACS reagent, 99,0 %), potassium chloride (for molecular biology, 99.0 %), potassium 
phosphate monobasic (plant cell culture tested, 99 %), magnesium sulfate heptahydrate (Plant 
Cell Culture Tested), sodium bicarbonate (Plant Cell Culture Tested), albumin, from bovine 
serum (BSA, 98 % (agarose gel electrophoresis, lyophilized powder, essentially fatty acid free, 
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essentially globulin free)) and dimethyl sulfoxide (BioReagent, for molecular biology, suitable 
for plant cell culture, 99.9 %) were purchased from Sigma-Aldrich. Ethanol (absolute) was 
purchased from Fisher. PBS (Phosphate Buffered Saline, 0.0067 M (PO4), For Cell Culture) 
was purchased from Lonza. Forskolin (Coleus forskohlii in DMSO) was purchased from Merck 
Millipore. Roswell Park Memorial Institute medium (RPMI, 1640), foetal bovine serum, 
HEPES buffer solution (1 M), sodium pyruvate (100 mM, 100X), L-Glutamine (200 mM, 
100X) and 2-mercaptoethanol (50 mM) were purchased from Invitrogen (Casbald, USA). 
Sodium alginate powder was purified according to the method proposed by de Vos et al42. 
Briefly, the commercial powder was dissolved in an aqueous solution of EGTA 1 mM to 
remove Mg2+ and Ca2+ cations. Subsequently, the solution was filtered and washed by HCl, 
chloroform and butanol to eliminate remaining ions and proteins. Finally, the purified alginate 
powder was obtained by adjusting pH to 7.0, adding absolute ethanol for precipitation and 
drying using a vane pump. 
Cell culture. Rat insulin-secreting cell line INS-1E sensitive to glucose stimulation was 
provided by Prof. Pierre Maechler (University of Geneva, Department of Cell Physiology and 
Metabolism) and Prof. Patrick Gilon (Université Catholique de Louvain, EDIN, 
Endocrinology, Diabetes and Nutrition division). The Roswell Park Memorial Institute 
medium (RPMI, 1640) used for the culture of INS-1E cells was supplemented with HEPES (10 
mM), sodium pyruvate (1 mM), glutamine (2 mM), 2-mercaptoethanol (0.05 mM) and 10 % 
of foetal bovine serum. Cells were incubated in 75-cm2 flasks (Costar, Lowell, USA) at 37°C 
in a humid atmosphere of 5 % CO2, and the medium was replaced by fresh one every 2 days. 
Once the cells were 100 % confluent (4 or 5 days), they were washed with PBS (Phosphate 
Buffer Saline) before treatment with a trypsin/EDTA mixture. Trypsinized cells were 
suspended in fresh medium for encapsulation. For further culture, cells were diluted and placed 
in new 75-cm2 flasks containing 15 mL of fresh culture medium with serum. 
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Cell encapsulation. The pH of the solutions used for cell encapsulation were previously 
adjusted to 7.4. 
Cell encapsulation in pure alginate microcapsules.  An INS-1E cell suspension was mixed 
with 3 wt.% sodium alginate. The final cell density was 1.1*106 cells mL-1. This mixture was 
dropped in a CaCl2 solution (100 mM) using sterilized 3.0 mL plastic Pasteur pipettes (VWR). 
The droplets were incubated for 5 min to obtain microcapsules with solid calcium alginate 
external crusts and inner cell-containing sodium alginate core. The microcapsules were finally 
recovered, placed in test tubes filled with fresh culture medium with serum and maintained in 
cell culture conditions (37 °C, 5 % CO2). 
Cell encapsulation in alginate@TiO2 microcapsules. The encapsulation procedure of INS-
1E cells in alginate@TiO2 microcapsules is showed in Figure 1 A. In detail, an INS-1E cell 
suspension was first mixed with 3 wt.% sodium alginate supplemented with titanium precursor 
(TiBALDH, 250 mM). The final cell density was 1.1*106 cells mL-1. This mixture was extruded 
into a buffered aqueous solution containing CaCl2 (100 mM) and PDDAC (100 mM). The 
droplets were incubated for 5 min to obtain microcapsules with a solid white crust. The 
microcapsules were finally recovered, placed in test tubes filled with fresh culture medium 
supplemented with serum and maintained in cell culture conditions (37 °C, 5 % CO2). 
Material characterization. Microcapsules were dried through supercritical drying with 
liquid carbon dioxide, after being incubated in 3 % glutaraldehyde and dehydrated with 
ethanol. Morphological properties were analyzed using field emission scanning electron 
microscopy (FE-SEM, JEOL JSM-7500F), after being sputter-coated with gold. The elemental 
composition of the internal core and external shell of alginate@TiO2 microcapsules was 
determined using an energy-dispersive X-rays (EDX) analysis system with an acceleration 
voltage of 15.00 kV and a working distance of 8 mm. 
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Cell viability. The viability of encapsulated INS-1E cells was monitored by their oxygen 
consumption using a Clark’s cell vessel (HansaTech). Briefly, 3 microcapsules were put in the 
device, containing 1.0 mL of fresh culture medium. The relative respiration of INS-1E cells 
was determined by oxygen consumption. The oxygen consumption of the INS-1E cells just 
after the encapsulation was set as the reference value (100 %). Cell survival was confirmed 
using fluorescein diacetate (FDA), a vital dye stain. INS-1E cells were incubated in FDA 
solution (5 µM) for 5 minutes at room temperature. Pictures were then taken using a 
fluorescence microscope (Multizoom AZ100, Nikon) either in brightfield mode or in 
fluorescent mode at 536/40 nm with a colour camera (DSRi1, Nikon). 
Glucose-stimulated insulin secretion. An evaluation of insulin secretion of the 
microcapsules with entrapped INS-1E cells was performed as a function of time. Briefly, 
culture medium was removed from test tubes containing hybrid microcapsules. Microcapsules 
were washed twice with Hank’s balanced sodium salt solution (HBSS) (114 mmol L-1 NaCl, 
4.7 mmol L-1 KCl, 1.2 mmol L-1 KH2PO4, 1.16 mmol L-1 MgSO4, 20 mmol L-1 HEPES, 2.5 mmol 
L-1 CaCl2, 25.5 mmol L-1 NaHCO3 and 0.2 % BSA, pH 7.2). The first wash was just a quick rinse, 
while for the second wash, the microcapsules  were incubated in HBSS for 2 hours at 37°C 
(5% CO2). Then, the secretagogues diluted in HBSS were added another 2-hour incubation. A 
glucose solution of 3 mM was used for the determination of basal insulin secretion level, while 
15 mM glucose and 15 mM glucose supplemented with 1 µM forskolin were used for 
stimulated secretion, using independent samples for each assay. The supernatants were finally 
recovered to measure insulin concentration using a Rat/Mouse Insulin ELISA Kit provided by 
Merck Millipore. 
Statistical analysis. The concentration of insulin secreted by encapsulated INS-1E cells 
when stimulated by 15 mM glucose (or 15 mM glucose supplemented with 1 µM forskolin) 
was compared to basal secretion (stimulation by 3 mM glucose). Results were analyzed by 
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unpaired Student’s t-test, using XLSTAT 2013 software (Addinsoft) and with p < 0.05 being 
considered as significant.  
 
RESULTS AND DISCUSSION 
Microcapsule formation and cell encapsulation. The cell-laden alginate@TiO2 
microcapsules were formed by dropping the mixture of alginate, TiBALDH and INS-1E cells 
into CaCl2 / PDDAC solution, as depicted in Figure 1A. When the drops were immersed into 
the solution, a series reactions took place in the outmost layer of the drops, resulting in the 
formation of microcapsules. The reactions mainly include three ones as listed in Figure 1C. 
The sodium alginate in the interface of the drops and the solution reacted with calcium ions by 
cross-linking to form calcium alginate shells around the drops. Simultaneously, PDDAC 
adsorbed on the formed calcium alginate shells by electrostatic force. The adsorbed PDDAC 
further induced the hydrolysis and condensation of the TiBALDH in the outmost layer of the 
drops to form a TiO2 layer. With the prolongation of incubation, three above-mentioned 
reactions continuously occurred to thicken the calcium alginate and TiO2 shells, and finally 
contributed to the formation of alginate@TiO2 microcapsules (Figure 1B). The INS-1E cells 
were mainly encapsulated in the core of alginate@TiO2 microcapsules which was most 
composed of biocompatible alginate. The calcium alginate and TiO2 shells could protect the 
encapsulated cells from immune defenders and maintain the nutrient diffusion and insulin 
secretion.             
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Figure 1. Formation of cell-laden alginate@TiO2 microcapsules. (A) Encapsulation 
procedure of INS-1E cells in alginate@TiO2 microcapsules. (B) Schematic diagram of an 
INE-1E cells-laden alginate@TiO2 microcapsules. (C) Ionic cross-linking of alginate and 
hydrolysis and condensation processes of TiBALDH in the formation of alginate@TiO2 
microcapsules. 
Material characterization. The morphology, structure and elemental composition of 
alginate@TiO2 microcapsules with encapsulated INS-1E cells were characterized. Pure 
alginate microcapsules with encapsulated INS-1E cells were set as a control. Both cell-laden 
microcapsules were supercritically dried with CO2, in order to preserve their original structure. 
The dried microcapsules were characterized using scanning electron microscopy (SEM) 
equipped with an energy-dispersive X-rays (EDX) analysis system.   
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Figure 2. Morphology and structure of a cell-laden alginate microcapsule. SEM 
micrographs of a cell-laden alginate microcapsule (A), its surface (B) and core (C), as well as 
encapsulated INS-1E cells (D). The microcapsule was incubated in culture medium for 6 
weeks, except for the microcapsule shown in B(ii) which was observed directly after 
preparation and set as a control. The microcapsules were supercritically dried with CO2 prior 
to analyses.              
Figure 2A depicts the SEM micrograph of a pure alginate microcapsule with encapsulated 
INS-IE cells after 6-week incubation in culture medium. The microcapsule shows spherical 
morphology with a diameter of ~2000 μm. Figure 2B (i) gives the enlarged SEM micrograph 
of the external surface of the microcapsules in which some cracks can be observed. On the 
contrary, a very smooth surface can be seen in pure alginate microcapsules without any further 
incubation (Figure 2B (ii)). The difference between the two surfaces indicates that the surface 
evolution of pure alginate microcapsules from smooth to cracked by long-term incubation, 
demonstrating the lack of long-term stability of pure alginate microcapsules. The cracks of the 
surface could resulted from the dissolution of calcium alginate layers or the degradation of 
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alginate cores. The core of the microcapsule presents a sponge-like structure with highly 
porosity (Figure 2C), which was formed by the loss of a large content of aqueous solution 
during the supercritically drying. This sponge-like structured core could not only provide 
enough space to be filled with nutrient for cell growth, proliferation and metabolism, but also 
maintain the mass transport and the cell-to-cell communication inside microcapsules. Figure 
2D shows encapsulated INS-1E cells in the microcapsule, confirming the presence of the cells 
in this cell-laden microcapsule.  
 
Figure 3. Morphology and structure of a cell-laden alginate@TiO2 microcapsule. SEM 
micrographs of a cell-laden alginate@TiO2 microcapsule (A), its surface (B) and core (C), as 
well as encapsulated INS-1E cells (D). The microcapsule was kept in culture medium for 6 
weeks and supercritically dried with CO2 prior to analyses.    
Figure 3A presents a cross-section of an alginate@TiO2 microcapsule, highlighting the 
presence of well dispersed cells in the core and a condensed shell. Figure 3B shows that the 
surface of the alginate@TiO2 microcapsules is still very dense without cracks even after 6-week 
incubation. The dense layer could be attributed to the adsorption of PDDAC and the formation 
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of TiO2. PDDAC is a positive charged linear polymer. When it was adsorbed on the surface of 
the microcapsules, it would contribute to the condensation of alginate on the outmost layer 
owing to its interaction with the negative charged alginate, thus consolidating the calcium 
alginate shell. Meanwhile, PDDAC induced the hydrolysis and condensation of TiBALDH to 
form a uniform and robust TiO2 layer which could further enhance the mechanical stability of 
shells. As a comparison, on the surface of pure alginate microcapsules some cracks of about 
10 µm are observed after 6-week incubation which is shown in Figure 2B(i). Since the 
molecular size of immunoglobulin G (IgG)43, the smallest defender of our immune system, is 
around 17-20 nm on the basis of the equation of Stokes44-46, these immunoglobulin molecules 
can easily penetrate through the cracks of 10 µm and kill encapsulated INS-1E cells 
encapsulated. In addition, these large cracks would lead to the leakage of encapsulated cells, 
thus decreasing functional activity of cell-laden microcapsules in cell therapy. Therefore, pure 
alginate microcapsules present serious defects in terms of stability to be applied in cell 
encapsulation towards cell therapy. Whilst alginate@TiO2 hybrid microcapsules remain intact 
after long-term incubation in culture medium, evidencing their enhanced mechanical stability 
and suggesting their more effective protection against immune defenders. The core of the 
alginate@TiO2 microcapsule (Figure 3C) presents the same structural properties as those of 
pure alginate microcapsules (Figure 2C), which indicates that the formation of TiO2 mainly 
occurred at the external surface of alginate microcapsules and would not influence the inner 
structure of alginate, thus confirming their biocompatible structure towards the encapsulated 
cells. It is worth to note that the encapsulated INS-1E cells were grouped into small clusters 
(Figure 3D), which is in the same manner as free cells during culture, in addition to the presence 
of extracellular matrix at their surface, thus suggesting a good health state of the encapsulated 
cells and proving biocompatibility of the alginate@TiO2 matrix.  
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Figure 4. Elemental composition of an alginate@TiO2 microcapsule. SEM micrographs of 
the core (A) and the shell (B) of an alginate@TiO2 microcapsule. EDX spectra and elemental 
percentage of the core (C) and the shell (D) of the alginate@TiO2 microcapsule. The 
microcapsule was supercritically dried with CO2 immediately after synthesis prior to analyses.    
EDX analyses were performed on alginate@TiO2 microcapsules to identify the elemental 
composition of the inner and the outer parts of the microcapsules. Figure 4 presents the 
morphology and EDX spectra of the inner core (A, C) and the external shell (B, D) of 
alginate@TiO2 microcapsule. The presence of the CKα, OKα and CaKα peaks in either the 
sponge-structured core (Figure 4A) or the dense shell (Figure 4B) indicates that the 
microcapsules are mainly made of alginate and calcium alginate. Ti element can be detected at 
the external surface of the alginate@TiO2 microcapsule (25.46 at.%) (Figure 4D), indicating 
that a TiO2 layer was formed around the microcapsule as a shell which could enhance the 
stability of microcapsules. A small portion of Ti element (5.32 at.%) can be detected in the 
core of the microcapsule (Figure 4C), which suggests that the formation of TiO2 also took part 
 15 
in the inner core but with a slow reaction rate due to the absence of polycations. The different 
percentage of Ti element between the core (5.32 at.%) and the shell (25.46 at.%) of the 
microcapsules confirms their core@shell structure which not only maintains the 
biocompatibility of the alginate core towards the encapsulated cells but also enhances the 
stability and mechanical strength of the microcapsules through the introduction of an inorganic 
shell for long-term applications.   
Cell viability. The viability of INS-1E cells encapsulated in either pure alginate or 
alginate@TiO2 microcapsules was monitored over time by the evaluation of oxygen 
consumption and FDA staining, in order to test the biocompatibility of the microcapsules 
towards encapsulated cells for their potential application in cell therapy.    
The oxygen consumption of encapsulated cells was measured using a Clark’s cell device. 
This parameter is directly proportional to the number of living cells in the microcapsules. 
Figure 5 presents the relative respiration as a function of time with 100 % corresponding to the 
oxygen consumption of INS-1E cells encapsulated in one microcapsule just after 
encapsulation. The viability of INS-1E cells was maintained for 6 weeks as the relative 
respiration slightly increased over the whole period. It is worth to note that the respiration 
activity of the cells encapsulated in alginate@TiO2 microcapsules increased up to ~250 %, 
whereas that of the cells encapsulated in pure alginate microcapsules remained ~100 %. The 
rapid increase in respiration activity of INS-1E cells encapsulated in alginate@TiO2 
microcapsules can be attributed to cell proliferation, suggesting very good biocompatibility of 
our designed hybrid microcaspules towards INS-1E cells. Please note that the relative 
respiration of alginate@TiO2 varied more largely at 14 days and 42 days, which could result 
from the shell crack of few alginate@TiO2 microcapsules after long-term incubation. Owing to 
the cell proliferation and the degradation of alginate core, the shell of few microcapsules 
appeared cracked after a long-time incubation, while the most others were still crack-free. Pure 
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alginate microcapsules are highly compatible towards encapsulated cells and support their 
growth and proliferation, however, the oxygen comsuption which can be linked to the number 
of living cells has not increased. One possible explanation of this phenomenon is the cell 
leakage from the pure alginate microcapsules due to the surface crack appearance of the most 
of the microcapsules upon incubation.  
 
Figure 5. Oxygen consumption of encapsulated INS-1E cells. Oxygen consumption of the 
INS-1E cells encapsulated in alginate and alginate@TiO2 microcapsules. 100 % corresponds 
to the oxygen consumption of INS-1E cells encapsulated within one microcapsule (1.3*102 
μmol h-1 microcapsule-1). Results are presented as means ± 1 S.D. (n = 3).    
The viability of the cells encapsulated in alginate@TiO2 microcapsules was further 
confirmed by the characterization of FDA-stained cells using fluorescent microscope. Living 
cells with intact plasma membrane can produce green fluorescein after stained by FDA due to 
the presence of active esterase in cytoplasm.  
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Figure 6. Viability of encapsulated INS-1E cells. Optical micrograph of the FDA-stained 
INS-1E cells encapsulated in alginate@TiO2 microcapsules 1-h (A), 35-day (C) and 42-day (E) 
post-encapsulation. Fluorescent micrograph of the FDA-stained INS-1E cells encapsulated 
within alginate@TiO2 microcapsules 1-h (B), 35-day (D) and 42-day (F) post-encapsulation.  
Optical and fluorescent micrographs of FDA-stained INS-1E cells encapsulated in 
alginate@TiO2 microcapsules are depicted in Figure 6. 1-h post-encapsulation, cells were 
homogeneously dispersed in microcapsules (Figure 6A) and more than 90 % of them were 
alive (Figure 6B). After 35 days, the encapsulated INS-1E cells were present as clusters in the 
microcapsules (Figure 6C and 6E), which was in accordance with the observations made by 
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SEM (Figure 3A and 3D) and the growth state of free cell in culture plate. In addition, the cell 
clusters exhibited green fluorescence (Figure 6D and 6F), demonstrating the high viability of 
the encapsulated cells. Combined with the results of oxygen consumption, it can be concluded 
that our designed alginate@TiO2 hybrid microcapsules, in comparison with pure alginate 
microcapsules, could be a better candidate as a cell resevoir to encapsulate INS-1E cells with 
long-term viability for the treatment of T1D.  
Glucose-stimulated insulin secretion. In order to evaluate the potential of our designed 
cell-laden alginate@TiO2 microcapsules used for the treatment of T1D, the insulin secretion of 
encapsulated INS-1E cells stimulated by glucose were studied by the measurement of insulin 
concentration in the supernatant of the secretagogue media 2- and 6-week post-encapsulation. 
Cell-laden pure alginate microcapsules were set as a control. The results were indicated as a 
stimulation index which is defined by the increase in insulin secretion when stimulated by 
glucose or glucose supplemented with forskolin minus the basal secretion. Forskolin is an 
activator of adenylate cyclase that stimulates the release of insulin.  
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Figure 7. Insulin secretion of encapsulated INS-1E cells. Insulin secretion of the INS-1E 
cells encapsulated in alginate (A) and alginate@TiO2 (B) microcapsules under the stimulation 
of glucose (15 mM) or glucose (15 mM) supplemented with forskolin (1 µM). Stimulation 
index is defined by the increase in insulin secretion (ng mL-1) when stimulated by glucose or 
glucose supplemented with forskolin minus the basal secretion (3 mM). Values are means ± 1 
S.D. (n = 3). * p < 0.05 compared to the basal insulin secretion.    
The stimulated insulin secretion of INS-1E cells encapsulated in alginate and alginate@TiO2 
microcapsules are presented in Figure 7A and 7B, respectively. Under the stimulation of only 
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glucose, the insulin secretion of the cells encapsulated in pure alginate microcapsules or in 
alginate@TiO2 microcapsules and incubated for 2 weeks shows no difference to that of basal 
levels, however, an increased insulin secretion could be detected for the cells encapsulated in 
the pure alginate microcapsules or in alginate@TiO2 microcapsules and incubated for  6 weeks 
because of cell proliferation. In order to confirm the responses of encapsulated cells to glucose 
more precisely, forskolin was used as an additive stimulator to amplify insulin secretion. After 
2-week or 6-week incubation for the cells encapsulated in pure alginate microcapsule and in 
alginate@TiO2 hybrid microcapsules, the insulin secretion stimulated with glucose 
supplemented with forskolin shows a highly significant difference (p < 0.05) in comparison 
with basal levels. Both experiments indicate that encapsulated INS-1E cells can significantly 
respond to glucose stimulation and maintain their metabolic activity. It is worth to note that the 
cells encapsulated in alginate@TiO2 microcapsules 6-week post-encapsulation show 
significantly increased insulin secretion levels compared to that 2-week post-encapsulation. 
The increase of insulin secretion over time was attributed to the enhanced metabolic activity 
of encapsulated cells and cell proliferation, supporting the results presented in Figures 4 and 5. 
Please note the cells encapsulated in pure microcapsules showed a less increase of insulin 
secretion levels between 2-week and 6-week post-encapsulation. This could result rather from 
the metabolic activity enhancement of encapsulated cells than cell proliferation, as the amount 
of encapsulated cells was not increased based on the result presented in Figure 5. In addition, 
this result evidences that alginate@TiO2 microcapsules displayed well adapted porosity for the 
entry of nutrients and the secretion of insulin. Although pure alginate microcapsules also allow 
the diffusion of nutrients and insulin as shown by the results presented in Figures 5 and 7, these 
microcapsules suffer from crack formation during incubation. These cracks could result in the 
cell leakage and the loss of their immune-isolation. 
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On the basis of the previous study39, alginate@TiO2 hybrid microcapsules, in comparison with 
the most-used pure alginate microcapsules, not only present long-term mechanical stability and 
high biocompatibility towards HepG2 cells, but also possess well-controlled porosity to 
maintain the nutrient diffusion and metabolic releasing of the encapsulated HepG2 cells. 
However, HepG2 cells are only a kind of model cells for the fundamental investigation and 
show no function in cell therapy. The practical application of alginate@TiO2 hybrid 
microcapsules in cell therapy still remains a lot of problems. In this work, the functional 
insulin-secreting INS-1E cells were first time encapsulated in alginate@TiO2 hybrid 
microcapsules, thus being further developped from the last research and much closer to the 
practical treatment of T1D. In the case of INS-1E cells, the core of the alginate@TiO2 hybrid 
microcapsules provided the encapsulated cells with a biocompatible aqueous environment for 
their growth, proliferation and metabolism. In addition, their robust TiO2 layer not only offered 
a long-term stability to prevent cell leakage, but also presented well controlled porosity for the 
diffusion of glucose as well as insulin secreted by the encapsulated cells (Figure 1B). This 
makes them an ideal reservoir of INS-1E cells for the controlled delivery of insulin in the 
treatment of T1D. 
 
CONCLUSIONS 
The highlights of this work can be summarized into the points listed below:  
• Alginate@TiO2 hybrid microcapsules were synthesized by the ionic cross-linking of 
alginate and the hydrolysis and condensation of TiBALDH, thereafter first time being applied 
to encapsulate rat insulinoma-derived INS-1E cells, aiming at the treatment of T1D.   
• Alginate@TiO2 hybrid microcapsules, compared to the most-used pure alginate 
microcapsules, demonstrated improved long-term stability and less cell leakage, making them 
a better reservoir for INS-1E cells to protect them from immune attacks for a long time.  
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• The rat insulinoma-derived INS-1E cells encapsulated in alginate@TiO2 maintained 
insulin secretion as a response to glucose stimulation 6-week post-encapsulation, evidencing 
the potential application of the cell-laden alginate@TiO2 microcapsules in the treatment of T1D.   
Consequently, alginate@TiO2 hybrid microcapsules could be an ideal reservoir for the 
encapsulation of INS-1E cells towards the treatment of the increasingly widespread T1D, as 
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